Key result
Observational study evaluates the link between elevated Lp(a) levels and epicardial adipose tissue volume.
Why the study?
The association between lipoprotein(a) levels and epicardial adipose tissue volume in people living with diabetes without ASCVD was unclear.
Is there an association between high Lipoprotein(a) levels and epicardial adipose tissue volume in people living with diabetes?
Observational (n=649)
Is there an association between high Lipoprotein(a) levels and epicardial adipose tissue volume in people living with diabetes?
Answers are grounded in this paper and cite their sources.
Observational study reveals a discordant relationship between lipoprotein(a) and epicardial adipose tissue volume in diabetes, suggesting separate cardiovascular risk pathways.
Lipoprotein(a) [Lp(a)] is a highly atherogenic lipoprotein whose structure drives its atherogenicity and pro-thrombotic and inflammatory properties.1 Lipoprotein(a) is an independent, causal, and significant marker of atherosclerotic cardiovascular diseases (ASCVDs).1 In people living with diabetes (PLWD), elevated Lp(a) contributes to both microvascular and macrovascular complications.2 In PLWD, increased epicardial adipose tissue (EAT) volume correlates with higher coronary artery calcium (CAC) scores,3 myocardial ischaemia,4 diabetic cardiomyopathy,5 and arterial stiffness.6 This study aimed to assess the association between Lp(a) levels and EAT volume in PLWD. We selected 649 patients (353 men, 54.4%) from the microEAT study, based on the available measurement of Lp(a) assessed by immunoturbidimetric assay, no history of ASCVD, who underwent electrocardiogram-gated cardiac computed tomography (CT) without contrast injection for CAC and EAT volume measurements in order to assess cardiovascular risk.3,4 Epicardial adipose tissue volume was estimated with Volume Viewer software package (proprietary prototype, GE HealthCare) and was measured using a semi-automatic segmentation technique on every axial slice from the thoracic inlet to the upper abdomen.3,4 The study was validated by the local ethical committee (CLEA-2020-148). An information sheet was sent to all potential participants, and those who did not oppose were included. The associations between high Lp(a) levels and patient characteristics were analysed using the nonparametric Mann–Whitney test for quantitative variables and the χ2 test or Fisher’s exact test for qualitative variables. To assess the independent relationship between Lp(a) levels and EAT volume, we performed a multiple linear regression. This model included the following variables: age, sex, body mass index (BMI), geographic origin, diabetes type, estimated glomerular filtration rate (eGFR), HDL cholesterol, triglyceride levels, and statin and sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment. Multiple imputation by chained equations was performed, with 10 imputations obtained after 10 iterations, to account for the missing data in the multivariable model. For all parametric analyses, EAT was log transformed, whereas the study cohort was dichotomized in two groups [high and low Lp(a)] defined according to a cut-off of 30 mg/dL.1 All tests were two-sided at a 0.05 significance level. Analyses were carried out using R statistical software version 4.2.2 (R Foundation for Statistical Computing; URL https://www.R-project.org/).
No takes yet. Share an insight, caveat, or question.
Gallo et al. (2026) conducted an observational in Diabetes (n=649). Lipoprotein(a) levels vs. Low Lipoprotein(a) levels (<30 mg/dL) was evaluated on Association between Lipoprotein(a) levels and epicardial adipose tissue volume. The abstract describes the methodology for an observational study assessing the association between Lipoprotein(a) levels and epicardial adipose tissue volume, but reports no quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: